• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两种不同类型的人抗体对凝血因子 VIII 凝血活性的灭活作用。

Inactivation of factor VIII coagulant activity by two different types of human antibodies.

作者信息

Gawryl M S, Hoyer L W

出版信息

Blood. 1982 Nov;60(5):1103-9.

PMID:6181833
Abstract

Human antibodies that inactivate factor VIII procoagulant activity (VIII:C) are heterogeneous in their kinetic properties. We report there here the properties of four type I and four type II antibodies classified according to Biggs et al. Type I antibodies have second-order inactivation kinetics and completely destroy VIII:C when present in high concentration; type II antibodies have more complex kinetics and do not completely inactivate VIII:C even when tested undiluted. The latter properties correspond to the in vivo finding in some patients that there is detectable VIII:C, even though there is also a significant inhibitor titer. It has been suggested that the antibody-antigen complex in these patients retains some VIII:C activity. This is unlikely, however, since protein-A-Sepharose (PAS) did not adsorb any VIII:C activity from mixtures of type II antibodies with normal human plasma. An alternate possibility, reduced VIII:C inactivation due to a steric effect the factor-VIII-related protein (VIIIR, von Willebrand factor), appears to be a more important factor, since three of four type II antibodies had inactivating properties like type I antibodies when they were tested with separated VIII:C instead of plasma. Although the fourth type II antibody did not completely inactivate separated VIII:C the residual coagulant activity was adsorbed from this mixture by PAS. These data indicate that type II anti-VIII:C react with different antigenic determinants than type I antibodies and that these determinants are partially blocked in the factor VIII complex by VIIIR.

摘要

使凝血因子VIII促凝活性(VIII:C)失活的人源抗体,其动力学特性具有异质性。在此我们报告根据比格斯等人分类的4种I型抗体和4种II型抗体的特性。I型抗体具有二级失活动力学,高浓度存在时能完全破坏VIII:C;II型抗体的动力学更为复杂,即使未经稀释检测也不能完全使VIII:C失活。后一种特性与一些患者的体内发现相符,即尽管存在显著的抑制剂效价,但仍可检测到VIII:C。有人提出这些患者体内的抗体 - 抗原复合物保留了一些VIII:C活性。然而,这似乎不太可能,因为蛋白A - 琼脂糖(PAS)不能从II型抗体与正常人血浆的混合物中吸附任何VIII:C活性。另一种可能性,即由于因子VIII相关蛋白(VIIIR,血管性血友病因子)的空间效应导致VIII:C失活减少,似乎是一个更重要的因素,因为4种II型抗体中有3种在用分离的VIII:C而非血浆进行检测时,具有与I型抗体相似的失活特性。尽管第4种II型抗体不能完全使分离的VIII:C失活,但PAS可从该混合物中吸附残留的凝血活性。这些数据表明,II型抗VIII:C抗体与I型抗体反应的抗原决定簇不同,并且这些决定簇在因子VIII复合物中被VIIIR部分阻断。

相似文献

1
Inactivation of factor VIII coagulant activity by two different types of human antibodies.两种不同类型的人抗体对凝血因子 VIII 凝血活性的灭活作用。
Blood. 1982 Nov;60(5):1103-9.
2
Immunological evidence that human factor VIII is composed of two linked moieties.人类凝血因子VIII由两个相连部分组成的免疫学证据。
Br J Haematol. 1977 Nov;37(3):415-28. doi: 10.1111/j.1365-2141.1977.tb01013.x.
3
The separation of Willebrand factor from factor VIII-related antigen.血管性血友病因子与VIII因子相关抗原的分离。
Br J Haematol. 1979 Jul;42(3):455-68. doi: 10.1111/j.1365-2141.1979.tb01154.x.
4
Rabbit antibodies against the procoagulant activity (VIII:C) of human factor VIII. Some theoretical and practical considerations on the human factor VIII molecule using heterologous antibodies.抗人凝血因子VIII促凝血活性(VIII:C)的兔抗体。关于使用异种抗体对人凝血因子VIII分子的一些理论和实际考量。
Thromb Haemost. 1981 Dec 23;46(4):699-705.
5
Gel filtration patterns of factor VIII coagulant antigen and factor VIII related antigen in normal and von Willebrand's disease.正常人和血管性血友病患者中凝血因子VIII促凝抗原及因子VIII相关抗原的凝胶过滤模式
Thromb Haemost. 1983 Aug 30;50(2):509-12.
6
Heterogeneity of autoantibodies to factor VIII: differences in specificity for apparently distinct antigenic determinants of factor VIII coagulant protein.抗凝血因子VIII自身抗体的异质性:针对凝血因子VIII凝血蛋白明显不同抗原决定簇的特异性差异。
Blood. 1983 Jul;62(1):133-40.
7
Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.人血浆中凝血因子 VIII 凝血蛋白的两种不同形式。凝血酶切割作用、凝血活性差异以及与血管性血友病因子的关联
J Clin Invest. 1984 Feb;73(2):307-16. doi: 10.1172/JCI111215.
8
Abnormal antigenic reactivity of factor VIII/von Willebrand factor subunit in variants of von Willebrand's disease.血管性血友病因子VIII/von Willebrand因子亚基在血管性血友病变异体中的异常抗原反应性。
J Lab Clin Med. 1982 Apr;99(4):481-94.
9
Immunologic studies of native and modified human factor VIII/von Willebrand factor.天然及修饰的人凝血因子VIII/血管性血友病因子的免疫学研究
Blood. 1979 Aug;54(2):310-21.
10
Heterogeneity of human procoagulant factor VIII (VIIIC) antibodies in their reaction with factor VIII related antigen (VIIIRAG).人促凝血因子VIII(VIIIC)抗体与因子VIII相关抗原(VIIIRAG)反应的异质性
Thromb Res. 1984 Jun 1;34(5):379-87. doi: 10.1016/0049-3848(84)90242-1.

引用本文的文献

1
Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A.获得性血友病A中,VIII因子抗体表现为I型或II型动力学。
Haemophilia. 2025 Mar;31(2):313-318. doi: 10.1111/hae.15144. Epub 2025 Jan 15.
2
A Rare Case of Hemophilia: Acquired Factor VIII Deficiency.血友病罕见病例:获得性VIII因子缺乏症
Cureus. 2024 Jun 14;16(6):e62407. doi: 10.7759/cureus.62407. eCollection 2024 Jun.
3
Diagnosis and laboratory monitoring of acquired hemophilia A.获得性血友病 A 的诊断和实验室监测。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):11-18. doi: 10.1182/hematology.2023000460.
4
Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay.不同凝血因子VIII抑制剂动力学特征对采用改良奈梅亨-贝塞斯达法测定抑制剂滴度的影响
Res Pract Thromb Haemost. 2022 Dec 12;6(8):e12799. doi: 10.1002/rth2.12799. eCollection 2022 Nov.
5
Acquired Haemophilia A: A Review of What We Know.获得性血友病A:我们所了解的综述。
J Blood Med. 2022 Nov 23;13:691-710. doi: 10.2147/JBM.S342077. eCollection 2022.
6
A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review.晚期黑色素瘤患者使用PD1/PDL1抑制剂后获得性血友病的诊断:两例患者的经验及文献综述
Diagnostics (Basel). 2022 Oct 21;12(10):2559. doi: 10.3390/diagnostics12102559.
7
Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.获得性血友病A:当前临床实践指南与经验
J Blood Med. 2022 May 11;13:255-265. doi: 10.2147/JBM.S284804. eCollection 2022.
8
International recommendations on the diagnosis and treatment of acquired hemophilia A.国际上关于获得性血友病 A 的诊断和治疗建议。
Haematologica. 2020 Jul;105(7):1791-1801. doi: 10.3324/haematol.2019.230771. Epub 2020 May 7.
9
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.实验室检测血友病患者的因子 VIII 和 IX 抑制剂:综述。
Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15.
10
High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.高滴度获得性因子V抑制剂伴多种凝血因子假性缺乏症表现
Intern Med. 2018 Feb 1;57(3):393-397. doi: 10.2169/internalmedicine.9150-17. Epub 2017 Nov 1.